Furthermore, recent studies have stated that Ezh2 overexpression is associated with aggressiveness and progression of different cancer types such as prostate, breast, bladder, and endometrial cancer, as well as melanoma (Bachmann et al., 2006; Clermont et al., 2017).Research on epigenetic therapy which has especially focused on DNMT and HDAC inhibitors as enlightened epigenetic mechanisms in cancer accelerated in the early 2000s. The gene discussed is EZH2; the disease is cancer.